BioRestorative Therapies, Inc.
BioRestorative Therapies is an emerging growth biopharma company focused on the research, development and commercialization of cellular therapies.
IR Website: https://www.biorestorative.com/ir/
Headquarters: Melville, NY
The company's first platform technology is focused on musculoskeletal health; it is developing an indication using an autologous cell based therapeutic product to address chronic degenerative disc disease and has received approval from the FDA to initiate a Phase 2 clinical trial. Its second platform technology addresses metabolic disease through an allogeneic cell based therapeutic product derived from Brown Fat Tissue and has indications in obesity, Type 2 Diabetes, and PCOS amongst other metabolic diseases. The Company has a robust pipeline of indications that will be leveraged across its two primary platform technologies.
TALK TO MANAGEMENT
The BioRestorative, Inc. management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
BioRestorative Therapies At-A-Glance
A Robust Pipeline for Myriad of Indications
Video: Interview with CEO Lance Alstodt
Video: BioRestorative Therapies underway with Phase 2 clinical trial with stem cell-based BRTX-100
Stock Chart (Intraday)
Stock Chart (Historical)
BRTX-100 and Chronic Lower Back Pain
Metabolism and Fighting Fat
Economic Value Add
Management Overview - A Proven Management Team
Risks & Disclosures
The BioRestorative Therapies management team and investor relations team is available to talk to current and potential investors. They're happy to answer your questions and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
• Directly hear the BioRestorative story
• Ask your questions
• Submit the form below and someone will get in touch with you as soon as possible
Note: Company management or its representative can only discuss and disclose information that is already available in the public domain. They will do their best to clarify such information to the extent permitted by securities law and industry regulations.